drugset / Trial / NCT01254773
Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease
Phase 2
Completed
146 enrolled
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Pfizer · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study in individuals with mild to moderate Alzheimer's Disease is designed to assess:(1) safety and tolerability (2) the capacity of subcutaneous bapineuzumab to reduce brain amyloid load as measured by positron emission tomography (PET) scans.
Timeline
- Start
- 2010-12
- Primary completion
- 2013-01
- Completion
- 2013-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | bapineuzumab | Monoclonal antibody | 2 mg | Subcutaneous |
| Subject | bapineuzumab | Monoclonal antibody | 7 mg | Subcutaneous |
| Subject | bapineuzumab | Monoclonal antibody | 20 mg | Subcutaneous |